News

The FDA has granted fast track designation to PLN-101095 plus pembrolizumab for ICI-refractory advanced or metastatic solid tumors.

During a Community Case Forum event, Manojkumar Bupathi, MD, MS, and participants discussed how drug interactions, cost, and day-to-day tolerability are what separate one ARPI regimen from another in hormone-sensitive prostate cancer.

The FDA has granted fast track designation to BH-30643, an oral OMNI-EGFR inhibitor, for advanced EGFR C797S-positive non–small cell lung cancer after a third-generation TKI.

Agentic AI streamlines oncology decisions and trial matching, cutting administrative load, flagging care gaps, and widening community access to studies.

The individualized neoantigen therapy intismeran autogene improved recurrence-free survival over pembrolizumab alone in patients with fully resected melanoma.

The FDA has granted fast track designation to ETX-19477, an oral PARG inhibitor, for BRCA-mutated, HR+/HER2– unresectable or metastatic breast cancer.

During a live event, Sudarsan Kollimuttathuillam, MD, and participants discussed how real-world practice for preventing febrile neutropenia in extensive-stage small cell lung cancer often runs ahead of formal risk stratification.

The designation is for sapanisertib/serabelisib (Piktor) plus chemo in patients who have progressed after chemo and an immune checkpoint inhibitor.

Following the FDA approval of vusolimogene oderparepvec plus nivolumab, melanoma specialists are preparing for real-world clinical use while rethinking how to design future intratumoral therapy trials.

Trastuzumab deruxtecan improved progression-free survival vs chemoimmunotherapy in the phase 3 DESTINY-Lung04 trial in HER2-mutant NSCLC.

UGN-103 NDA targets recurrent low-grade NMIBC; phase 3 UTOPIA reports 77.8% complete response and 94.5% 6-month durability.

Savolitinib plus osimertinib met PFS and OS end points vs chemotherapy in the phase 3 SAFFRON trial of EGFR-mutated, MET-driven NSCLC.

FDA reviews OST-HER2 survival data for potential accelerated approval for preventing recurrent metastatic osteosarcoma after lung surgery.

A retrospective cohort study of metastatic castration-sensitive prostate cancer found no difference between the ARPI agents overall, but a signal for survival benefit in those aged 75 or older.

A guide to breast cancer biomarker testing, from ER/PR and HER2-low status to PIK3CA, AKT1, and ESR1 mutations across diagnosis and disease progression.

The multicenter PRO B trial found that weekly ePRO monitoring with alert-based nurse contact reduced fatigue vs usual care in metastatic breast cancer.

A secondary analysis of the phase 3 RxPONDER trial found that premenopausal women with low baseline AMH did not benefit from added chemotherapy vs endocrine therapy alone.

Sagar Lonial, MD, provides commentary on the key questions raised by recent data on lenalidomide maintenance for patients with newly-diagnosed multiple myeloma.

"New clinical evidence helps clarify which patients can benefit from radiation therapy,” said Daniel Chang, MD.

Phase 2 data show atezolizumab delivers durable responses in relapsed/refractory NK/T-cell lymphoma, with PD‑L1 markers helping predict benefit.

NeOnc's intranasal NEO100 met its primary end point in a phase 2a trial of recurrent IDH1-mutant glioma, reaching 48.9% 6-month PFS vs a 20% benchmark.

Cancer centers face rising outpatient demand; learn how smarter scheduling, better data, and AI-driven capacity planning ease flow, staffing strain, and complex therapy coordination.

Robert L. Ferris, MD, PhD, highlights how a virtual behavioral health program embedded in oncology care improved patients' QOL.

The iberdomide-daratumumab-dexamethasone regimen was approved based on superior MRD negativity rate vs standard of care in relapsed/refractory multiple myeloma.

Zipalertinib plus platinum-based chemotherapy significantly improved progression-free survival at a planned interim analysis of the phase 3 REZILIENT3 trial.

Registry data show bulky lymphoma drives different treatment choices and mixed survival effects, highlighting the need to standardize tumor bulk definitions.

During a live event, Eric K. Singhi, MD, and participants discussed how CNS activity and cumulative toxicity, not guideline listing alone, are shaping frontline treatment selection in ROS1-positive advanced NSCLC.

The FDA has granted breakthrough device designation to Freenome's SimpleScreen Lung, an investigational blood-based test for high-risk lung cancer screening.